Dana Bakalar1†
Jiaqi J. O’Reilly2
Helene Lacaille2
Jacquelyn Salzbank2
Jacob Ellegood3Jason P. Lerch4
Toru Sasaki1†
Yuka Imamura5
Kazue Hashimoto-Torii1
Claire-Marie Vacher2*‡
Anna A. Penn2*‡- 1Center for Neuroscience Research, Children’s Research Institute, Children’s National Health System, Washington, DC, United States
- 2Division of Neonatology, Department of Pediatrics, NewYork-Presbyterian Morgan Stanley Children’s Hospital, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, United States
- 3Mouse Imaging Centre (MICe), Hospital for Sick Children, Toronto, ON, Canada
- 4Wellcome Centre for Integrative Neuroimaging (WIN), Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom
- 5Department of Biochemistry and Molecular Biology, Pennsylvania State University College of Medicine, Hershey, PA, United States
Placental endocrine function is essential to fetal brain development. Placental hormones include neurosteroids such as allopregnanolone (ALLO), a regulator of neurodevelopmental processes via positive allosteric modulation of the GABAA receptor (GABAA-R). Using a mouse model (plKO) in which the gene encoding the ALLO synthesis enzyme is specifically deleted in trophoblasts, we previously showed that placental ALLO insufficiency alters cerebellar white matter development and leads to male-specific autistic-like behavior. We now demonstrate that the lack of placental ALLO causes female-predominant alterations of cortical development and function. Placental ALLO insufficiency disrupts cell proliferation in the primary somatosensory cortex (S1) in a sex-linked manner. Early changes are seen in plKO embryos of both sexes, but persist primarily in female offspring after birth. Adolescent plKO females show significant reduction in pyramidal neuron density, as well as somatosensory behavioral deficits as compared with plKO males and control littermates. Assessment of layer-specific markers in human postmortem cortices suggests that preterm infants may also have female-biased abnormalities in cortical layer specification as compared with term infants. This study establishes a novel and fundamental link between placental function and sex-linked long-term neurological outcomes, emphasizing the importance of the growing field of neuroplacentology.
Introduction
A key role of placental hormones in neurodevelopment has long been hypothesized (1–3). Placental dysfunction (e.g. due to infection or malperfusion) and premature loss of the placenta (i.e. preterm birth) are associated with abnormal brain development and neurological and cognitive deficits, even in late-preterm infants who are not otherwise ill (2, 4–9). One important placental hormone is allopregnanolone (3α,5α-tetrahydroprogesterone or ALLO), which derives from progesterone via a two-step enzymatic pathway concluding with the action of 3α-hydroxysteroid dehydrogenase (3α-HSD), an enzyme encoded by the akr1c14 gene in mice. ALLO levels increase during mid-to-late pregnancy in both mother and fetus (10, 11), and although the brain can produce ALLO from its precursors starting near term (12–14), fetal ALLO is primarily placental in origin (15).
ALLO is a potent allosteric modulator of the ligand-gated GABAA receptor (GABAA-R), a receptor involved in the regulation of many neurodevelopmental processes such as neurogenesis, cell survival, cell migration and synaptogenesis (16–22). ALLO has been shown to control cell proliferation in multiple model systems and cell types via its action on GABAA-Rs (23). Treatment with ALLO acts on intermediate progenitor cells (IPCs), increasing proliferation in the cortical subventricular zone (SVZ) and down-regulating genes that promote cell cycle exit (22, 24, 25).
Fetal brain ALLO levels peak in mid-to-late gestation (15, 26, 27), which coincides with the formation and expansion of the cerebral cortex. In mouse, placental expression of the akr1c14 gene is highest at about embryonic day (E) 15 (15), a stage at which the number of IPCs quickly expands in the SVZ (28, 29). IPCs give rise to post-mitotic newborn excitatory pyramidal neurons that will migrate to the upper layers (layers II-IV, or ULs) of the developing cortex (30). IPCs express GABAA-Rs, enabling GABAergic regulation over their proliferation, differentiation and the migration of their daughter cells (31), further suggesting a role for ALLO during development. Human studies reported a similar rise in fetal ALLO during mid-to-late gestation (32, 33), coinciding with active IPC production in the SVZ (34). In humans, the ratio of UL versus deeper layer (DL) neurons is extraordinarily high, and likely contributes to cortical gyrification (35, 36), suggesting that loss of ALLO may cause significant damage to human neurodevelopment. In the present study, we have tested the hypothesis that insufficient placental ALLO affects cerebral cortex development in mouse and human. Loss of placental ALLO in preterm infants during this critical window of corticogenesis is a potential devastating factor for the developing brain, contributing to the etiology of prematurity cognitive disorders.
Much of previous research relied on pharmacologically manipulating ALLO levels, which differs from directly altering de novo ALLO during development. ALLO’s actions at GABAA-Rs are concentration-dependent (37), so supplementing ALLO can change its pharmacodynamics and alter downstream signaling pathways (18, 38–41). Studies blocking ALLO via pharmacological agents present compelling findings for a role of ALLO during development, but this approach alters a wide class of other hormones (42–44). Importantly, these pharmacological approaches could not specifically assess the placental contribution of ALLO to fetal neurodevelopment. The Cre-Lox akr1c14Cyp19 KO (plKO) mouse model that we recently developed overcomes these limitations by its tissue specificity, enabling us to isolate the consequences of placental ALLO insufficiency on brain development. Using this model, we have previously found that placental ALLO supports cerebellar white matter development, and that its depletion increases the risk of Autism Spectrum Disorders (ASD)-like features in male, but not female, progeny (15). Since much of corticogenesis occurs embryonically, when fetal (placental) ALLO is high, we aimed to determine if placental ALLO contributes to the development of the cortex.
Here we demonstrate in the plKO mouse model that reduced placental ALLO production results in predominantly female impairments of cortical development, in particular in the primary somatosensory cortex (S1). Furthermore, the analysis of human postmortem cortical specimens suggests that preterm birth causes similar sex-biased disruption in the upper-layer formation. Overall, our study shows that placental hormones such as ALLO support fetal brain development in a sex- and region-dependent manner, and that their loss may contribute to long-term neurobehavioral outcomes of prematurity.
Materials and methods
Mice
Animal care and use accreditations
Animals were group housed with a 12 hour light/dark cycle and ad libidum access to food and water. Mice were bred and maintained at the Association for Assessment and Accreditation of Laboratory Animal Care International accredited Children’s National Research Institute Animal Facility. All experiments and procedures were done in compliance with the Animal Welfare Act, the regulatory requirements of the NIH Office of Laboratory Animal Welfare and the US Department of Agriculture and were approved by the Institutional Animal Care and Use Committee [protocol no. 30534 (PI: Penn)]. Children’s National Research Institute has currently approved Animal Welfare Assurance Agreements with the PHS Office of Laboratory Animal Welfare [D16-00219 (A3338-01)].
Akr1c14-floxed mice
The akr1c14-floxed mouse (akr1c14fl/fl) was created by Ingenious Targeting Laboratories (Ronkonkoma, NY, USA), as previously described (15).
Cyp19-Cre mice
The Cyp19-Cre mouse line (#5912 line), which expresses Cre exclusively in trophoblast cells, was obtained from Dr. Gustavo Leone, Ohio State University (45).
Akr1c14Cyp19 (plKO) mice
The akr1c14Cyp19aKO (plKO) mouse was generated by successive crosses from progenitor akr1c14-floxed and Cyp19-Cre animals. Homozygous Cyp19-Cre females were crossed to homozygous akr1c14-floxed males. Resulting females (hemizygous for Cre and heterozygous for LoxP sites flanking akr1c14) were mated to homozygous akr1c14-floxed males. Female offspring homozygous for LoxP and positive for Cre were crossed with homozygous akr1c14-floxed males, resulting in experimental animals, the plKO mice and littermate controls (Ctrl). The generation and genetic validation of the plKO mice has been previously described (15). Both male and female offspring were used in all studies described. The body weight was monitored across postnatal development into adulthood for all genotypes.
PCR genotyping
Genomic DNA was extracted using the Extracta DNA Prep for PCR kit and genotyped with AccuStart II GelTrack PCR SuperMix (Quanta Biosciences, Gaithersburg, MD, USA). Primers used to genotype and sex animals are available in Supplementary Table 1. PCR was run in a 2720 ThermoCycler (Applied Biosystems, Waltham, MA, USA) with the following program: 94° for 3 minutes; (94° for 30 seconds, 60° for 30 seconds, 72° for 1 minute) x 30 cycles; 72° for 10 minutes.
Human samples
The NIH NeuroBioBank (University of Maryland, Baltimore, MD) provided the frozen human Brodmann Area 10 cortex samples (request ID #709). Donors comprised 6-week-old term infants (average age) and corrected age matched preterm infants. Those with major congenital anomalies or known genetic diagnoses, and those with meningitis or stroke as cause of death were excluded. The sex, completed gestational weeks and cause of death varied, but the majority were caused by sudden infant death syndrome, with no CNS infection, hemorrhage or malformation noted. Donors’ information were previously reported in (46).
BrdU and EdU labeling of proliferating cells
Proliferating cells were labeled in utero (at E15.5, determined by observation of vaginal plugs, the day of plug being E0.5) by maternal intraperitoneal injection of BrdU (50 mg/kg of maternal body weight; Thermo Fisher Scientific, Waltham, MA, USA) or EdU (123 mg/kg; Thermo Fisher Scientific) (47) dissolved in sterile normal saline solution. 10% DMSO was added to dissolve EdU in the saline solution.
Tissue collection
Embryonic brains
Gestational age was determined by observation of vaginal plugs (the day the plug was observed is day 0.5). For collection of embryonic tissue, dams were euthanized using carbon dioxide exposure followed by cervical dislocation. Embryos were then dissected out and decapitated. Brains were removed from the skull and either post-fixed in 4% paraformaldehyde (PFA) for 1-2 days, then transferred to 30% sucrose at 4° until equilibrium (for immunohistochemistry), or flash frozen in liquid nitrogen and stored at -80° until use (for Western blots).
Postnatal brains
At P30, animals were euthanized either via carbon dioxide asphyxiation or by transcardial perfusion with 4% PFA under deep isofluorane anesthesia. For RNA extractions, cerebral cortex was dissected and flash frozen with liquid nitrogen and stored at -80°C until use. For immunohistochemistry, brains were post-fixed overnight in 4% PFA at 4°C. All fixed tissues underwent a sucrose gradient of 10%, 20% and 30% over three days at 4°C.
3’mRNA-sequencing
Tissue collection and RNA extraction
Bilateral cerebral cortex from Ctrl and plKO mice (males and females; 3 animals/group) were dissected at P30 and flash frozen. Tissue homogenization and total RNA extraction were performed using the mirVana Isolation kit (Thermo Fisher Scientific; #AM1560) as per the manufacturer’s instructions.
Library Preparation, Sequencing for mRNA and Data Analysis
All the procedures have been described previously (15). The data have been deposited in NCBI’s Gene Expression Omnibus and are accessible through GEO Series accession number GSE173440. Principal component analysis and scatter matrices revealed no outliers in our biological replicates. Differentially expressed genes had to meet the following criteria: p<0.05; fragments per kb of transcript per million mapped reads values more than one; and fold change greater than 1.5. These cutoffs’ limits were validated using qRT-PCR on cortical samples from both similar and different mouse cohorts. Ingenuity Pathway Analysis (Qiagen, Redwood City, CA, USA) was used to identify the top differentially regulated biological functions and disease processes.
qRT-PCR
Mouse S1 somatosensory cortex and human Brodmann Area 10 tissues were homogenized in TRIzol™ Reagent (Thermo Fisher, Waltham, MA, USA; #15596018); total RNA was extracted with the RNeasy Mini Kit (Qiagen Venlo, The Netherlands; #74104) and quantified with a Nanodrop ND-2000C (Thermo Fisher). 1 μg of RNA was used to make cDNA with the iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA, USA; #1708891). All primer pairs were designed and validated in-house for efficiency and specificity. RT-PCR experiments were performed on cDNA samples in presence of SsoAdvanced Universal SYBR Green Supermix (Bio-Rad; #1725271) with specific primers at 100 nM using the ABI Prism 7500 Sequence Detection System (Thermo Fisher). The cDNA-generated signals for target genes were normalized with the glyceraldehyde 3-phosphate dehydrogenase (gapdh). Primers used for qRT-PCR are available in Supplementary Table 1. The regulation was determined with the 2–ΔΔCq method. Results are expressed as fold change compared to the control group.
Western blots
Protein extracts from E15.5 female cortices were harvested by sonication in 1× RIPA lysis buffer and quantified for concentration using the Pierce BCA protein assay (Thermo Fisher Scientific). 25 μg of proteins were separated by SDS-PAGE and transferred onto PVDF membranes (0.2-μm-large pores) using the Bio-Rad system. Blots were blocked for one hour with 5% non-fat dry milk in TBS with 0.1% Tween-20 (TBS-T) and incubated overnight at 4°C in 3% BSA in TBS-T with antibodies against: BCL-2 (1:1,000; Cell Signaling, Danvers, MA, USA; #2772), BAX (1:1,000; Cell Signaling; #2772) or β-tubulin (1:2,000; Cell Signaling; # 2146). HRP-conjugated secondary antibodies, mouse IgG kappa binding protein (1:2,000; Santa Cruz; #sc-51602) or anti-rabbit IgG (1:2,000; Cell Signaling; #7074) were incubated for one hour, and chemiluminescence was detected using Clarity Western ECL Substrate on a Bio-Rad ChemiDoc MP imaging system. Using ImageJ software (http://rsb.info.nih.gov/ij/), all targets were analyzed densitometrically relative to β-tubulin loading control, and then were normalized to the average density of all bands within each blot to account for inter-run variability.
Immunohistochemistry
Brains used for immunohistochemistry were sectioned coronally at 20 µm (embryonic brains) or 40 µm (P30 brains) using a sliding microtome (Thermo Fisher Scientific). EdU incorporation was detected by reaction with azide-conjugated Alexa555, following manufacturer instructions (Click-iT EdU Alexa Fluor 555 Imaging Kit, Thermo Fisher Scientific). Briefly, sections were incubated for 30 min in the dark in freshly made Click-iT reaction cocktail and then washed in PBS containing 0.3% Triton-X (PBST). BrdU, when used, was uncovered by a 30 min NAOH 2N submersion, followed by washing in PBST. Sections were blocked for 1.5 hours at room temperature in PBST containing 10% normal donkey serum and 0.3% Triton X-100, before being incubated overnight at 4° with primary antibodies. The next day, sections were washed 3 times with PBST and incubated in secondary antibodies at room temperature for 1.5 hours, then washed as before and mounted in Fluoromount-G mounting medium (Southern Biotech, Birmingham, AL, USA). Staining was performed using the following primary antibodies: BrdU (1:500; Abcam; #ab6326), COUP-TF-interacting protein 2 (Ctip2; also called BCL11B; 1:500; Novus biologicals, Littlecon, CO, USA; #NB100-2600), Special AT-rich sequence-binding protein 2 (Satb2; 1:250; Abcam; #ab51502), Cut like homeobox 1 (Cux1; also called CDP; 1:1,000; Santa Cruz; #sc-6327), Forkhead box protein P2 (FoxP2; 1:1,000; Abcam; #ab16046), Ki67 (1:250; Abcam; #ab15580) or phospho-Histone 3 (pH3; 1:500; Santa Cruz; #sc-56745). The following secondary antibodies were used at 1:2,000: donkey anti-mouse Alexa-488 (Invitrogen; #A-21202), donkey anti-rabbit Alexa-488 (Invitrogen; #A-21206), donkey anti-mouse Alexa-555 (Invitrogen; #A-31570), donkey anti-rabbit Alexa-555 (Invitrogen; #A-31572), donkey anti-mouse Alexa-647 (Invitrogen; #A-31571), donkey anti-rabbit Alexa-647 (Invitrogen; #A-31573).
Imaging and quantification
Imaging procedures
Brain sections were selected to sample the developing and adult somatosensory cortex. Embryonic sections were selected from the middle of the embryonic brain’s rostral caudal axis [Allen Developing Brain Reference Atlases, TS24 (E15.5) and TS25 (E17.5)]. A minimum of two sections from each animal were analyzed in each staining, and the counts were averaged to provide the final data used. For postnatal brain sections, four images were taken of the barrel subfield of S1 in each hemisphere of each cortex (based on the Allen Brain Reference Atlas), and data from these images was averaged. Confocal images (Z-stacks of between 5 and 8 1-2-μm optical sections) of all sections were acquired with an Olympus FV1000 laser scanning confocal microscope through a 20× oil objective. Four different laser lines were used for imaging: FITC (488 nm excitation; 522/35 emission filter), Cy3 (560 nm excitation; 605/32 emission filter), Cy5 (647 nm excitation; 680/32 emission filter) and DAPI (400 nm excitation). All counting was performed by an individual blind to group allocation of the animals.
Cell proliferation assays
Mitosis was examined by staining for pH3 (marking mitotic cells), and the number of pH3+ cells in a 450-µm by 350-µm ROI including the ventricular zone of the cortex was assessed. Imaris-Bitplane software (South Windsor, CT, USA) was used for embryonic cell counts. Cells were identified using the “spots” function. The “colocalize spots” plugin was further used to identify co-localization of antigens. Spot criteria were adjusted until visible cells were counted but background was not. Cells identified by the program were visually assessed and false positives (marking fibers, bright areas of background and other aberrations) were manually removed. To assess proliferation of Ctip2+ and Satb2+ neurons, confocal images were cropped using ImageJ to a 400 μm-wide ROI spanning the cortical plate vertically. Within this ROI, total cells identified with Imaris as double positive for both BrdU and Ctip2, or for BrdU and Satb2 were divided by the total number of BrdU+ neurons in each image, to yield a ratio of proliferating cells bound for upper versus lower cortical layers.
Cell cycle kinetics
Cell cycle kinetics in E15.5 mice were assessed using Imaris software in combination with manual counting in an ROI (of variable size) incorporating the VZ and SVZ. The technique is described in detail in (48, 49). Briefly, the dam was injected with EdU at Time 0. Cells in S-phase at this time incorporate the EdU. Later, a second injection with BrdU is done and cells in S-phase at this time are marked. The cells remaining in S-phase at the time of dissection (Scells) are BrdU+, while cells that left the cycle prior to the BrdU injection (Lcells) are EdU+/BrdU-. With Ti as the interval between the injections, the length of S-phase (Ts) can be calculated (50) as follows: Ts = Ti/(Lcells/Scells). Then the length of the cell cycle (Tc) can be estimated using the number of total proliferating cells, here labeled with Ki67 (Pcells) as follows: Tc = Ts/(Scells/Pcells).
Assessment of cortical upper and deep layer principal cell densities
In P30 brains, a 750-μm-wide ROI containing the full vertical span of S1 cortex was assessed for number of Cux1+ and Foxp2+ cells. Cell densities were determined by using the ImageJ “Find Maxima” application on the clearest image in each z-stack. Tolerance was adjusted until visible cells were counted but background was not. The density of Cux1+ cells was calculated in layers II-IV of the S1 and the density of FoxP2+ cells was calculated in layers V/VI by dividing cell count by the area of the defined layers. Layer identity was determined based on DAPI counter-staining.
Magnetic resonance imaging (MRI)
The procedures were the same as previously described and the current cortical data was obtained from the same set of brains as in (15).
Brain preparation
Anesthetized P30 mice were perfused intracardially with 30 mL of 0.1 M PBS containing 10 U/100 mL heparin (Sigma) and 2 mM ProHance (gadolinium contrast agent, Bracco Diagnostics, Monroe Township, NJ, USA), followed by 30 mL of 4% paraformaldehyde (PFA) and 2 mM ProHance. Following perfusion and decapitation, brains in skulls were postfixed in 4% PFA and 2 mM ProHance at 4°C overnight and then kept in PBS with 2 mM ProHance and 0.02% sodium azide for at least one month prior to MRI scanning (51, 52).
Diffusion tensor image (DTI) acquisition
Brain imaging was performed using a multi-channel 7 Tesla MRI scanner (Agilent Inc., Palo Alto, CA, USA). For DTI Imaging, brains were scanned with a 3D diffusion-weighted FSE scan (53, 54). The DTI sequence parameters were as follows: TR of 270 ms, echo train length of 6, intial TE of 32 ms, and a TE of 10 ms for the remaining 5 echoes, 1 average, FOV of 14 mm × 14 mm × 25 mm and a matrix size of 180 × 180 × 324 resulting in an image with 78 µm isotropic voxels. Using the Jones30 scheme (55), five b=0 s/mm2 images and 30 high b-value (b=2147 s/mm2) were acquired in 30 different directions. The entire imaging duration was about 12 hours. The FSL software package (FMRIB, Oxford, UK) was employed to generate fractional anisotropy and mean diffusivity (MD) maps for each brain sample.
MRI registration and analysis
The b=0 s/mm2 images were registered linearly (6 followed by 12 parameter) and non-linearly to determine any alterations to the mouse brains owing to genotype and sex. Registrations were carried out using a combination of mni_autoreg tools (56) and ANTS (advanced normalization tools) (57). After registration, all scans were resampled using an appropriate transform to create a population atlas depicting the average anatomy of the study samples. The final registration results in the individual images deformed into unbiased alignment with one another. Individual DTI parameter analyses compared intensity differences of MD between genotype and sex.
Behavioral phenotyping
Animals underwent a series of behavioral tests beginning between 35 and 37 days of age, and completed the series within a two-week period. One test was carried out per day in the sequence described below at P35, P36 and P37 respectively.
Open field
Animals were habituated to the testing room for one hour, and then placed individually in the open field apparatus and recorded for 30 minutes. The open field was made up of a 16x16 square grid of 4 square inches. Mice were recorded from above with a USB webcam. Videos were analyzed with ANY-Maze software (Stoelting, Wood Dale, IL, USA). Average speed and total distance travelled during the trial were measured to assess overall activity level and motor function. Proportion of time spent in the central area (consisting of the central 4 squares in the grid) versus the surrounding squares was determined to assess anxiety and exploratory behavior. After testing, each animal was removed to a holding cage until all animals from the home cage had been tested. Between animals, the apparatus was wiped down with 70% ethanol.
Continuous spontaneous alternations Y-Maze
Spontaneous alternation is a simple, hippocampus-dependent task measuring working memory (58, 59). After habituation to the testing room for one hour in its home cage, the mouse was placed in the center of a Y-maze with arms labeled A, B and C, and allowed to freely explore. Arm choice was recorded by an observer blind to the genotype of the animal during an 8-minute period. The mouse was then removed to a holding cage (identical to the home cage) until all animals from the home cage had been tested to minimize disruption to animals yet to be tested. Between animals, the apparatus was cleaned with 70% ethanol. Spontaneous alternation behavior was scored by determining the number of three unique arm entries (alternation) divided by the total number of arm entries minus 1 (59).
Somatosensory novel object discrimination
This task is a modification of a standard novel object test (60) in which the animal is presented with two identical objects and then, following a period of time, with one of the original objects and a novel object. It tests recognition memory, a non-spatial memory paradigm. We ran this test under infrared light, to exclude the effects of vision and specifically test somatosensory system function. The initial objects were columns (2 inches high and 1 inch in diameter) made of hard plastic. The novel object was a large plastic binder clip, placed with metal prongs upright. This test was filmed from above and analyzed using ANY-Maze. Each animal was exposed to the initial objects under infrared light for 10 minutes on day 1 of testing. Following a 12-hour break, animals were exposed to one novel and one familiar object for ten minutes, with the side each was presented on systematically varied. After testing, each animal was removed to a holding cage until all animals from the home cage had been tested. Between animals, the apparatus was cleaned with 70% ethanol. Recognition Index (RI), which corresponds to the ratio between the time spent exploring the new object relative and the total exploration time, was assessed.
Statistical analysis
Data analysis was performed using GraphPad Prism version 6.00 for Windows (GraphPad Software, www.graphpad.com). First, outliers over 2 standard deviations from the mean were excluded, and then normality of remaining data was assessed by the D’Agostino-Pearson normality test. For normal data, either 2-way ANOVA, followed by Sidak’s or unpaired Student’s t-test followed by Tukey post-hoc testing was used. Bonferroni corrections were used for multiple t-tests. For nonparametric data, we used the Mann-Whitney test. Expression data over time was analyzed with one-way ANOVA with tests for linear trend. Mean diffusivity (MD) data were analyzed for each cortical region using three-way ANOVA to assess the interaction effect between genotype, sex and region. Tukey’s method was used for multiple comparison post-hoc testing. Summary data are presented in the text as mean ± SEM from n animals. The p-values reflecting the likelihood of association between the experimental differentially expressed genes and diseases/functions given by Ingenuity Pathway Analysis were calculated using a right-tailed Fisher’s exact test. Differences were considered significant at p<0.05. Replicate numbers, p values and statistical tests used for each analysis are indicated in the figure legends. All measurements were performed in mice of both sexes and statistically analyzed by sex except where indicated.
Results
Cortical transcriptome is altered in adolescent mice following placental ALLO insufficiency
RNA-sequencing on whole cerebral cortex at P30 identified 162 upregulated and 169 downregulated genes in plKO males as compared with their littermate controls (Figure 1A; Supplementary Figure 1A; Supplementary Table 2 sheet 1). In P30 females, we found 242 upregulated and 262 downregulated genes in plKO compared to control mice (Figure 1B; Supplementary Figure 1B; Supplementary Table 2 sheet 2). Ingenuity Pathway Analysis of the significantly dysregulated genes showed significant disruption of myelin-related functions in plKO males (Figure 1C; Supplementary Table 3A), consistent with our previous findings on cerebellar white matter development alterations in plKO mice (15). Neural cell proliferation/survival/differentiation/migration pathway clusters also appeared among the top disrupted pathways in the plKO mice of both sexes, but in females more genes were altered (Figure 1; Supplementary Tables 3, 4). Other commonly disrupted pathways involved neurophysiology, neuritogenesis and astrocytic functions (Figures 1C, D; Supplementary Tables 3, 4). In the RNAseq analysis, akr1c14 gene expression was unaltered in the P30 cerebral cortex (Supplementary Table 2 sheets 1 and 2). Likewise, the levels of akr1c14-mRNA in the embryonic brain (at E14.5 and E17.5) and the postnatal cerebral cortex (from P0 to P15) were not different in plKO mice as compared with littermate controls (Supplementary Figure 2), suggesting that neither gene deletion nor regulation occurs in the plKO cortex, and thus ALLO production in the brain of plKO and control mice should be similar.
Figure 1 Impact of placental ALLO insufficiency on the cerebral cortex transcriptome at P30. (A, B) MA plots for the cortical RNAseq analysis of plKO vs Ctrl mice at P30 in males (A) and females (B). M, log ratio; A, mean average. DEGs are represented as colored dots (blue for males and magenta for females). (C, D) Top 15 significant enriched gene functional groups identified with Ingenuity Pathway Analysis software (Qiagen) in males (C) and females (D). P-values were calculated using right-tailed Fisher’s exact tests.
Placental ALLO insufficiency causes long-term reduction of the mean diffusivity (MD) in specific cortical areas
Diffusion Tensor Imaging (DTI) was performed to investigate variations in cortical structural integrity throughout the different cortical areas. MD, which quantifies the rotationally invariant magnitude of water diffusion within the tissue, was compared between control and plKO mice at P30. Factorial ANOVAs were conducted to compare the main effects of genotype, sex and cortical area as well as their interactions on MD. In the somatosensory cortex, a significant effect of genotype on MD was found (F(1,390)=14.45, p=0.0002; Figure 2). There was also a significant interaction effect between genotype and sex (F(1,390)=4.727, p=0.0303). Post-hoc Tukey’s multiple comparison test revealed that MD was significantly lower in the female plKO than in female controls (p=0.0005). In the entorhinal areas, comparable, although less significant effects of genotype and sex × genotype interaction were seen (genotype: F(1,234)=6.095, p=0.0143; sex × genotype interaction: F(1,234)=6,987, p=0.0088; Supplementary Figure 3A). Multiple comparison tests found that MD was reduced in female plKO as compared with their controls (p=0.0043; Tukey’s test). Significant effects of genotype, without interaction with sex, was found in the cingulate (F(1,390)=10.31, p=0.0014; Supplementary Figure 3B) and orbital (F(1,156)=4.114, p=0.0442; 3-way ANOVA) cortices (Supplementary Figure 3C). In contrast, MD in frontal and motor areas was not significantly different in plKO as compared with control mice (not shown). Collectively, these results indicate that placental ALLO loss is associated long-term microstructural changes of the cerebral cortex, with females being particularly vulnerable in areas such as the somatosensory cortex.
Figure 2 Diffusion Tensor Imaging (DTI) analysis in the somatosensory cortex of Ctrl and plKO mice at P30. Heatmap representing mean diffusivity (MD) across the different somatosensory areas. MD was significantly decreased in the female plKO somatosensory cortex, as compared with their littermate controls. Data presented in a hierarchical tree. Three-way sex by genotype by region ANOVA: main genotype effect: ★★★★★p<0.0005; sex × genotype interaction: #p<0.05. Tukey’s multiple comparison test: ****p<0.001. n = 11 M Ctrl, 8 F Ctrl, 13 M plKO, 11 F plKO. F, female; M, male.
The density of upper-layer S1 neurons is durably altered in plKO female mice
Based on our DTI characterization of the plKO brain which identified sex-linked MD changes in the somatosensory cortex, we next examined the cyto-architectonic organization of the primary somatosensory cortex (S1). Principal neuron populations were assessed using the post-mitotic layer markers Cux1 and FoxP2, which label UL and DL pyramidal neurons, respectively. A significant reduction of Cux1+ neurons in the UL S1 was seen in P30 plKO females as compared with littermate controls, but not in males (Males: p=0.32; Females: p=0.01; Sidak’s multiple comparison test; Figures 3A, B). In contrast, there was no significant difference in the density of DL FoxP2+ cells by genotype or sex (Figures 3A, C). This data shows that the lack of placental ALLO alters the S1 UL neurons in a sex- and layer-dependent manner.
Figure 3 Long-term effect of placental ALLO insufficiency on cortical lamination. (A) Representative immunofluorescent staining for Cux1 (red) and FoxP2 (cyan) in the female S1 area at P30. (B, C) Quantification of (A) shows that the density of Cux1+ upper layer principal cells is significantly decreased (layers II-IV) in plKO females but that the density of FoxP2+ deeper layer principal cells remained unaltered. n = 8-15 M Ctrl, 5-12 F Ctrl, 6-9 M plKO, 7-14 F plKO. Data presented as mean ± SEM. Two-way sex by genotype ANOVA with Sidak’s post-hoc comparison test: *p < 0.05 identified in magenta for females. Cux1, Cut like homeobox 1; F, female; FoxP2, Forkhead box protein P2; M, male. DL, deep layer; UL, upper layer.
Long-term, female-specific behavioral impact of placental ALLO insufficiency
To assess the somatosensory function of plKO mice, P30 mice underwent a modified novel object recognition (NOR) test. The NOR task was performed under infrared light to exclude the use of visual cues (Figure 4A). Recognition Index, the ratio of the time spent exploring the new object relative to the total exploration time, was assessed. The Recognition Index was significantly decreased in plKO females but not in males, as compared with sex-matched littermate controls (Males: p=0.84; Females: p=0.007; Sidak’s multiple comparison test; Figure 4B), suggesting that plKO females were less able to discriminate between the known and novel objects due to altered somatosensory processing, potentially linked to the anatomical changes noted in S1. PlKO mice, however, did not differ from controls in tests of activity (open field) (Figures 4C–E) and spatial memory (Y-maze) (Figures 4F, G).
Figure 4 Long-term effect of placental ALLO insufficiency on behavior. (A) Schematic diagram of the novel object recognition test, designed to assess the somatosensory function. (B) Female plKO mice have significant deficits in the novel object recognition task, as measured by the recognition index (RI), which corresponds to the ratio between the time spent exploring the new object relative and the total exploration time. n = 12 M Ctrl, 8 F Ctrl, 10 M plKO, 8 F plKO. Data presented as mean ± SEM. (C) Diagram of open field paradigm. (D) Total distance travelled by Ctrl and plKO mice in open field test. (E) Time spent in center quadrants of the open field. n = 6 M Ctrl, 9 F Ctrl, 8 M plKO, 6 F plKO. (F) Diagram of alternating Y-maze. (G) Alternation score (# alternations/# of possible alternations x 100). n = 9 M Ctrl, 14 F Ctrl, 7 M plKO, 5 F plKO. Data presented as mean ± SEM. Two-way sex by genotype ANOVA with Sidak’s post-hoc comparison test: **p < 0.01 identified in magenta for females. Illustrations in (A, C, F) were prepared using BioRender.com.
Additional physiological and behavioral assessments included growth and reproduction function. Body weight was monitored across postnatal development until adulthood, but was not influenced by genotype (Supplementary Figure 4). As previously reported, both mothering and mating behaviors appeared unaltered (15).
Placental ALLO insufficiency disrupts proliferation dynamics in the S1
GABA signaling has a strong trophic effect in the developing cortex (19) and ALLO, as a GABAergic modulator, has been implicated in the regulation of neural progenitor cell proliferation and neurogenesis (21, 22, 61, 62), so embryonic neurogenesis was assessed in the S1 in embryos with placental ALLO loss compared to normal placental exposure. Insufficiency in placental ALLO in plKO mice is detected as early as E14.5 and persists until at least E17.5 (15), which corresponds to a critical window for UL neurogenesis in the mouse cerebral cortex.
We first examined cell proliferation in the SVZ at E15.5, when ALLO insufficiency in plKO mice is the greatest and UL corticogenesis begins. Mitosis, assessed by phospho-Histone 3 (pH3) immunostaining, was similar in controls and plKOs at E15.5 (Males: p=0.91; Females: p=0.92; Sidak’s multiple comparison test; Figures 5A, B). To assess whether the lack of placental ALLO was associated with increased apoptosis, we tested the E15.5 cortex for the ratio of the pro-apoptotic protein BAX and the anti-apoptotic protein BCL2 in females (63, 64). There was no significant change in this ratio (Supplementary Figure 5), indicating normal levels of apoptosis in plKO S1.
Figure 5 Influence of placental ALLO insufficiency on mitosis and cell cycle kinetics in the cerebral cortex during mid-to-late gestation. (A) Immunofluorescent staining of pH3, a mitotic marker, in the cerebral cortex at E15.5. (B) Quantification of (A) reveals no change in the proportion of SVZ cells undergoing active mitosis in the plKO cerebral cortex at E.15.5. n = 8 M Ctrl, 6 F Ctrl, 5 M plKO, 7 F plKO. (C) Overview of experiments to determine cell cycle exit and kinetics at E15.5. (D) The different phases of cell cycle. (E) Immunofluorescent staining of EdU (magenta), marking proliferating cells at E15.5, dual pulsed with BrdU (green), injected 3 hours later, to identify cells in cycle and cells that had exited. (F) Quantification of the cell cycle exit ratio in the SVZ shows a significant loss in cell cycle exit in plKO mice at E15.5. (G) Significant increase in the SVZ cell cycle length (Tc) in plKO females associated with an (H) elongated S-phase (TS). n = 6 M Ctrl, 5 F Ctrl, 4 M plKO, 5 F plKO. Data presented as mean ± SEM. Two-way sex by genotype ANOVA with Sidak’s post-hoc comparison test: *p < 0.05 identified in magenta for females. F, female; M, male; pH3, phospho-Histone 3; SVZ, subventricular zone.
Since no change in cell proliferation or death was found, we next asked whether cell cycle exit and kinetics were altered by reduced placental ALLO exposure. Dual pulse labeling experiments were carried out as follows: EdU was injected at E15.5 and BrdU 3 hours later, and embryos were then collected one hour after the last injection (Figures 5C, D). Cell cycle exit ratio, defined by the ratio of (EdU+BrdU-)/EdU+, was reduced in female plKOs compared to controls in the SVZ, although not reaching statistical significance (Males: p=0.28; Females: p=0.06; Sidak’s multiple comparison test; Figures 5E, F). Cells had significantly longer cell cycles (TC) in female plKOs compared to controls (Males: p=0.12; Females: p=0.03; Sidak’s multiple comparison test; Figure 5G), due to significantly longer S-phase (TS; Males: p=0.18; Females: p=0.02; Sidak's multiple comparison test; Figure 5H). Regulation of the S-phase is typically the main driver of cell cycle length (65). However, TS was only 90 minutes longer in plKO females as compared with controls, and cannot fully explain the 2½ hour increase of TC, suggesting that other phases of cell cycle are also elongated.
Placental ALLO insufficiency impairs the production of UL neurons in the S1
To investigate the consequences of altered cell cycles on the production of cortical plate neurons, we next assessed the production of E15.5 born neurons at E17.5 (marked by BrdU; Figure 6A). The layer markers Ctip2 and Satb2 were used to identify early-born, DL-bound principal cells and late-born, UL-bound principal cells, respectively (66–68). There was no difference in the ratio of Ctip2+ BrdU+ cells relative to total BrdU+ cells, indicating that the E15.5 born neurons destined for deep layers were produced and migrated normally (Figures 6B, C). In contrast, between E15.5 and E17.5, 30% fewer proliferating E15.5 cells became UL, Satb2+ neurons in the plKO S1 compared to controls (p=0.0072; 2-way ANOVA; Figures 6B, D), showing that placental ALLO insufficiency primarily affects UL cortical development in the embryonic period.
Figure 6 Effect of placental ALLO insufficiency on cortical neurogenesis. (A) Overview of the experiments: BrdU was injected at E15.5, and embryos were euthanized at E17.5. (B) Determination of the localization of proliferating E15.5 cells (BrdU, green) by co-staining with Satb2 (red) upper layer principal cell marker and Ctip2 (cyan) lower layer principal cell marker. (C) Quantification of (B) shows that while deeper layers were unaltered, (D) fewer E15.5 born cells localized to the upper layers of the cortical plate. n = 5 M Ctrl, 4-5 F Ctrl, 3-4 M plKO, 4-5 F plKO. Data presented as mean ± SEM. Two-way sex by genotype ANOVA with Sidak’s post-hoc comparison test. Main effect of genotype: ★★p < 0.01. Ctip2, COUP-TF-interacting protein 2; F, female; M, male; Satb2, Special AT-rich sequence-binding protein 2. SVZ, sub-ventricular zone.
Cortical layering tends to be altered in female preterm infants
We investigated whether human preterm birth, which results in acute, early loss of placental endocrine support, was also associated with altered cortical lamination. We examined 22 post-mortem specimens comprising Brodmann Area 10 from term (>37 weeks of gestation) and preterm (<34 weeks of gestation) infants that died at an average corrected age of 6 weeks (Supplementary Figure 6A). We found that the ratio of cux1-mRNA to foxP2-mRNA levels tend to be decreased in the preterm females but not the males (Males: p=0.96; Females: p=0.09; Sidak’s multiple comparison test; Supplementary Figure 6B). The female-specific trend toward reduction of UL/DL neuronal ratio parallels our rodent findings, although significance at p<0.05 was not reached, possibly due to the small sample size available.
Discussion
Children born prematurely are at higher risk for developing cognitive difficulties in areas such as perceptual-motor function, learning and memory, attention, and social cognition. Since the placenta is lost prematurely in all preterm births, we have hypothesized that absence of late gestation placental factors could be a contributing factor. We have specifically investigated the role of placental ALLO in neurodevelopment because this neurosteroid is primarily produced by the placenta during late gestation, crosses the blood brain barrier, and has known neurotrophic properties. We created and validated a placenta-specific KO mouse line (plKO), in which placental ALLO production and resulting placental and brain ALLO levels are reduced (15). Here we show that placental ALLO insufficiency impairs cortical development at cellular and functional levels, with greater and persistent alterations in female cortex, and female neurosensory behavioral changes. These findings contrast with our previously reported findings of greater male susceptibility to cerebellar myelination changes with an ASD-like phenotype (15). Susceptibility to white matter decrements in males and cortical grey matter loss in females born preterm has been reported (69). Together these findings emphasize the need to examine sex, region and cell type specificity when examining the neurological impact of placental dysfunction.
Our unbiased approach to examining postnatal plKO cortex at multiple scales, from transcriptomics to MRI, revealed that placental ALLO loss is associated with long-term, sex-linked molecular and structural alterations. RNA sequencing analyses of the total cerebral cortex indicated greater dysregulation of neuronal and myelin development-related pathways in females and males, respectively, although there were many shared alterations on other pathways as well.
The current transcriptomic analysis suggests that white matter alterations occur not only in the cerebellum (15) but also across the brain in male plKOs. Although brain myelination is primarily a postnatal process, oligodendrocyte lineage cells are mostly produced embryonically (70), when placental ALLO is highest. Previous studies have shown the critical role played by ALLO in the development and maturation of oligodendrocyte lineage cells through GABAA-R signaling (71). It is not surprising, then, that ALLO insufficiency during fetal life disrupts brain myelination in plKO mice. A full characterization of the plKO white matter tracts is now needed to determine whether myelination impairments are consistent across brain regions, and how sex influences myelination trajectories.
Female mice lacking placental ALLO exhibit impaired cell cycling in the SVZ at E15.5, consistent with ALLO’s known actions on neurogenesis (22, 67, 72). Additional downstream modulators of neurogenesis, such as BDNF or IGF-1, both regulated by ALLO (73, 74), may also contribute to altered neurogenesis in response to ALLO deficits. ALLO is known to promote neurogenesis by upregulating genes that shorten cell cycle length (22) via GABA mediated downstream calcium signaling (75), it is thus likely that the mechanism underlying plKO alterations is also GABAergic. During early development, GABA has a potent trophic effect in the cerebral cortex (19). When gestational ALLO is high, GABAAR-mediated responses depolarize progenitor cells and immature neurons due to high intracellular chloride concentration (31, 76), increasing excitability and stimulating spiking and Ca2+ entry. Calcium entry can then activate a variety of signaling cascades controlling cell proliferation, migration, neuritogenesis, and synaptogenesis (77). The lengthened cell cycles in the SVZ of plKO females may reflect a delayed cortical maturation because cell cycle length normally decreases over time (78). Prolonged cell cycle may also indicate that IPCs undergo quiescence, which can persist for at least 48 hours (79). Ultimately, cells in S-phase will undergo mitosis, with cell cycle length determining the fate of divisions. Shorter cell cycle length is associated with a pro-differentiating progenitor state (80), while prolonged cell cycle shift IPCs toward self-renewal (75, 81). Further investigation is needed to determine whether IPCs in plKOs are shifted toward proliferation; such a change would result in a loss of differentiated UL neurons, as seen in plKO mice.
A major feature of the mammalian neocortex is its laminar organization, with each layer displaying distinct connectivity and function (35). Reduced cortical thickness in multiple areas, including the S1, is common in human preterm survivors (82–85), but specific layer alterations have not been elucidated. In plKO mice, the density of S1 UL neurons born at E15.5 was decreased at P30 in females. However, no evidence of resultant increased DL cell production or density, nor apoptosis, was found. This difference may lie in the timing of DL versus UL cell production. The formation of the cortical DL and UL takes place at E11.5-E14.5 and E13.5-E16.5, respectively (86). In control placentae, the expression of akr1c14 peaks at E14.5, which coincides with the most pronounced ALLO insufficiency in plKO mice (15). Thus, in our model, the impact of placental ALLO insufficiency on corticogenesis is expected to peak at E14.5, a stage at which the production of cortical DL neurons is nearly complete, while the UL population is still actively expanding. In plKO mice, the UL-specific alteration was seen as early as E17.5 with a reduction of the layer II/III Satb2+ cells born at E15.5 in both sexes. This decrease persisted at P30 with a deficit in Cux1+ neurons in the females. Cortical layer specification underlies specific patterns of axonal projections. Satb2 and Cux1 both enable the specification of callosal projection neurons (68, 87). In the human cortex, Cux1+ UL cells are still being produced at gestational week 23, near the lower limit for premature survival, and migrate until gestational week 37 (88). Lack of placental ALLO upon premature birth in infants might interrupt proliferation and migration of the future callosal neurons. Our molecular analysis of cortical lamination in preterm infants lends some initial support to this hypothesis since the ratio of the UL marker Cux1 on the DL marker FoxP2 tends to decrease in females.
Ultimately, loss of UL principal neurons has wide-ranging effects on S1 function because of the hierarchical nature of somatosensory information processing. Thalamo-cortical projections target layer IV neurons, which innervate layer II/III cells that feed-forward onto layer V for integration and output to other cortical regions (89). In mice, barrels of layer IV are somatotopically mapped for individual whisker (90, 91) while layer II/III plays an essential role in regulating layer V excitation during tactile whisker response (92). In plKO females, the UL cortical cell deficit in the S1 could underlie significant impairment in the whisker-specific, novel object recognition task. Alternative explanations for this specific deficit include decreased preference for novelty or altered memory, rather than a somatosensory deficit, but the plKO mouse showed no avoidance for novelty, spending equivalent time in the center of the open field test as control mice, and investigated arms of the Y-maze with the same frequency. Thus, somatosensory-specific functioning is impaired following placental ALLO insufficiency, correlating with the observed anatomical changes. Survivors of premature birth often have functional deficits in somatosensory processing too (93), which impair their social behavior, motor skills, and ability to complete tasks of daily living (94–97). Additionally, reduced connectivity (altered UL, callosal neurons) associated with Attention Deficit Disorder (98) or Autism Spectrum Disorders (ASD) (99) are commonly seen in premature infants (100–102). The extent of these behavioral impairments in preterm survivors is associated with cortical thickness (83) as well as with sex-dependent effects in somatosensory processing (93). Our findings bolster previous theories that loss of neurons in the S1 underlies deficits in somatosensory activity in preterm infants (103).
Our DTI analysis showed reduced MD in the somatosensory cortex of female plKOs, suggesting long-term, area- and sex-linked changes in cortical microstructure. However, the precise nature of the histological substrate underlying this altered DTI remains unclear. Given our transcriptomic and cellular analyses, we would expect that neuronal density is a substantial contributing element. However, prior studies comparing histology and neuroimaging data have shown that MD can correlate positively with neuronal density, at least in the hippocampus (104), complicating this interpretation of MD. Based on our RNAseq Ingenuity Pathway Analysis results, other contributing factors could include altered neurite and radial glia fiber development, which will be investigated in the future. Additionally, although our DTI analysis of the plKO cortex suggests altered microstructural integrity in the female S1, it also indicates that such anomaly may not be limited to the S1, but may affect other cortical areas such as the entorhinal cortex. Broader investigation of additional cortical functions is now required to decipher the global impact of placental ALLO insufficiency on the development of cognitive functions.
A striking sexual dimorphism was seen in the S1 development of mice lacking placental ALLO. In plKO mice, deficits in neurogenesis, cortical lamination and somatosensory function are more significant and long-lasting in the female than in the male progeny, revealing an increased female cortical vulnerability to placental ALLO insufficiency. Although placental ALLO levels and brain akr1c14 gene expression are similar between sexes, an accentuation of sexually distinct features seems to take place in the plKO brain (15). For instance, a marked sex-divergence in the myelination rate was seen in the plKO cerebellum (15). In several brain regions, females express fewer GABAA-R subunits and less glutamic acid decarboxylase (105, 106), and GABA has been proposed as a pivotal factor in the divergence of male vs female neurodevelopment (107). In particular, the capacity of GABA to change neuronal excitability in a depolarizing rather than hyperpolarizing manner may have major implications for a neuron’s phenotype, activating diverse signal transduction pathways and eventually resulting in varied gene expression. Sex-linked differences in receptor and transporter distribution or maturational state may contribute to sex-linked differences in response to GABA or its loss. For instance, in mice, the female brain is more sensitive to ALLO-mediated GABAergic neurotransmission potentiation, which contributes to enhanced neuroprotection from ischemia (108). Whether cortical GABAergic signaling is altered in plKO mice and contributes to the sex differences in their cortical phenotype is an area of active investigation.
The lack of placental ALLO may represent a contributing factor to various neurological disorders following prematurity or impaired placental function, with temporal and sex-linked effects on corticogenesis and somatosensory function. Our findings in mouse and human cortex further suggest that loss of placental ALLO could contribute to the sexually dimorphic outcomes of preterm birth. The DTI and RNAseq analyses of the plKO brain also indicate that placental ALLO insufficiency may alter broader cellular processes that vary by brain regions. Further investigation of the plKO brain development will provide valuable knowledge for future development of therapeutic strategies aimed at preventing long-term neurodevelopmental disorders that result from loss of placental function.
Data availability statement
The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found below: https://www.ncbi.nlm.nih.gov/, GSE173440.
Ethics statement
Ethical review and approval was not required for the study on human participants in accordance with the local legislation and institutional requirements. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements. The animal study was reviewed and approved by Children’s National Research Institute, Washington, DC 20010 USA.
Author contributions
DB, JO’R, C-MV, and AP designed research. DB, JO’R, HL, JS, JE, YI, and C-MV performed research. DB, JO’R, JE, JL, TS, YI, KH-T, C-MV, and AP analyzed data. DB, JO’R, C-MV, and AP wrote the paper. All authors contributed to the article and approved the submitted version.
Funding
This work was funded by National Institutes of Health grants R01HD092593 and 3R01HD092593-S1 (AP) and F31HD098886 (JO’R), the DC-IDDRC U54HD090257 (PI: Gallo), the Children’s National Board of Visitors (AP) and the Research Foundation of Cerebral Palsy Alliance (no. 3720; AP).
Acknowledgments
We thank Dr. G. Leone for providing us with the first Cyp19a-Cre mouse breeders. We also would like to express our gratitude to the families for their donation to the NIH NeuroBioBank, as well as to J. Cottrell (NIH NeuroBioBank), who assisted us with tissue selection. We thank William Yakah for his help with data presentation. We thank the Children’s Research Animal Facility, directed by J. Bradford, for taking care of our mouse colonies. We also acknowledge the support of the DC-IDDRC headed by Dr. Vittorio Gallo. In particular, we would like to thank the DC-IDDRC Animal Neurobehavioral Core, led by Dr. J. Corbin, for providing advice, space and equipment to conduct the behavioral phenotyping of our mice, and the DC-IDDRC Cell and Tissue Microscopy Core, headed by Dr. Jyoti Jaiswal, for providing access to light and confocal microscopes and image processing software. We would also like to acknowledge the Ontario Brain Institute (OBI) for financial support (JE and JL).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fendo.2022.972033/full#supplementary-material
Supplementary Figure 1 | Impact of placental ALLO insufficiency on the cerebral cortex transcriptome at P30. (A, B) Heatmaps of the significant differentially expressed genes at P30 in Ctrl and plKO samples, in males (A) and females (B). Genes and samples were hierarchically clustered based on Pearson distance of z-score data and average linkage. n=3 independent samples/group.
Supplementary Figure 2 | Time-course changes in akr1c14 gene expression in the embryonic brain and postnatal S1 somatosensory cortex. Akr1c14-mRNA level fold changes to E14.5 male control mean, determined by qRT-PCR and after normalization to ywhaz. Data presented as mean ± SEM. F, females; M, males; ywhaz, Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Zeta. Data presented as mean fold change ± SEM. Two-way age by genotype and sex ANOVA with Sidak’s post-hoc comparison test. Main effect of age: p<0.0001.
Supplementary Figure 3 | Diffusion Tensor Imaging (DTI) analysis by cortical area in Ctrl and plKO mice at P30. Heatmaps representing mean diffusivity (MD) throughout the different cortical areas. (A) Significant effects of genotype and sex × genotype interaction were found in the entorhinal cortex (3-way ANOVA). MD was significantly decreased in the female plKO as compared with littermate controls (Tukey’s test). A main genotype effect, with no significant interaction with sex, was seen in the cingulate (B) and orbital (C) cortices. Three-way sex by genotype by region ANOVA: main genotype effect: ★p<0.05, ★★★p<0.005; sex × genotype interaction: ##p<0.01. Tukey’s multiple comparison test: ***p<0.005. n=11 M Ctrl, 8 F Ctrl, 13 M plKO, 11 F plKO. F, female; M, male.
Supplementary Figure 4 | Body weight in the Ctrl and plKO males (A) and females (B) across early postnatal development and adulthood. Data presented as mean ± SEM. Two-way age by genotype repeated measures ANOVA with Sidak’s post-hoc comparison test. Main effect of age in males and females: p<0.0001.
Supplementary Figure 5 | Apoptosis rate in the plKO cerebral cortex at E15.5. (A) Western blot analysis of the pro-apoptotic protein BAX and the anti-apoptotic protein BCL2. (B) Quantification showing that there is no change in the BAX/BCL2 ratio relative to β-tubulin in plKO female mice as compared with controls. n=5 Ctrl and 6 plKO. Data presented as mean ± SEM. Mann-Whitney test. BAX, BCL2 Associated X protein; BCL2, B-cell lymphoma-2 protein.
Supplementary Figure 6 | Preterm birth is associated with dysregulation of layer-specific marker expression in the Brodmann Area 10. (A) Schematic of the age terminology during the perinatal period used for the human study. (B) Cux1-mRNA/FoxP2-mRNA ratio determined by qRT-PCR. n=9 male term, 4 female term, 4 male preterm, 5 female preterm. Data is presented as mean fold-changes ± SEM. Two-way sex by term ANOVA with Sidak’s post-hoc comparison test. (A) was created with BioRender.com.
Supplementary Table 1 | Sequences of the PCR primers.
Supplementary Table 2 | List of the significantly dysregulated genes in the cerebral cortex of P30 plKO males (sheet 1) and females (sheet 2), as compared with their littermate controls.
Supplementary Table 3 | (A, B) Top 15 significant enriched pathways in plKO cerebral cortex with p-Values and associated genes. Enriched gene functional groups identified with Ingenuity Pathway Analysis software (Qiagen) in males (A) and in females (B).
References
1. Knox K, Leuenberger D, Penn AA, Baker JC. Global hormone profiling of murine placenta reveals secretin expression. Placenta (2011) 3(11):811–6. doi: 10.1016/j.placenta.2011.08.013
2. Pasca AM, Penn AA. The placenta: The lost neuroendocrine organ. NeoReviews (2010) 11(2):e64–377. doi: 10.1542/neo.11-2-e64
3. Reuss ML, Paneth N, Susser M. Does the loss of placental hormones contribute to neuro-developmental disabilities in preterm infants? Dev Med Child Neurol (1994) 36(8):743–7. doi: 10.1111/j.1469-8749.1994.tb11918.x
4. Coe CL, Lubach GR. Vital and vulnerable functions of the primate placenta critical for infant health and brain development. Front Neuroendocrinol (2014) 35(4):439–46. doi: 10.1016/j.yfrne.2014.03.004
5. Kratimenos P, Penn AA. Placental programming of neuropsychiatric disease. Pediatr Res (2019) 86(2):157–64. doi: 10.1038/s41390-019-0405-9
6. Mallard EC, Rees S, Stringer M, Cock ML, Harding R. Effects of chronic placental insufficiency on brain development in fetal sheep. Pediatr Res (1998) 43(2):262. doi: 10.1203/00006450-199802000-00018
7. Penn A, Koss W, Agrawal M, Volate S, Leuenberger D, Kiraly M, et al. Placental hormone contribution to fetal brain damage. Placenta (2014) 35(9):A52. doi: 10.1016/j.placenta.2014.06.171
8. Perrone S, Toti P, Toti MS, Badii S, Becucci E, Gatti MG, et al. Perinatal outcome and placental histological characteristics: A single-center study. J Maternal-Fetal Neonatal Med (2012) 25(sup1):110–3. doi: 10.3109/14767058.2012.664344
9. Vohr B. Long-term outcomes of moderately preterm, late preterm, and early term infants. Clinics Perinatol (2013) 40(4):739–51. doi: 10.1016/j.clp.2013.07.006
10. Gilbert Evans SE, Ross LE, Sellers EM, Purdy RH, Romach MK. 3α-reduced neuroactive steroids and their precursors during pregnancy and the postpartum period. Gynecol Endocrinol (2005) 21(5):268–79. doi: 10.1080/09513590500361747
11. Luisi S, Petraglia F, Benedetto C, Nappi RE, Bernardi F, Fadalti M, et al. Serum allopregnanolone levels in pregnant women: Changes during pregnancy, at delivery, and in hypertensive patients. J Clin Endocrinol Metab (2000) 85(7):2429–33. doi: 10.1210/jcem.85.7.6675
12. Mellon SH. Neurosteroid regulation of central nervous system development. Pharmacol Ther (2007) 116(1):107–24. doi: 10.1016/j.pharmthera.2007.04.011
13. Petraglia F. Endocrine role of the placenta and related membranes. Eur J Endocrinol (1996) 135(2):166–7. doi: 10.1530/eje.0.1350166
14. Reis FM, Petraglia F. The placenta as a neuroendocrine organ. In: The endocrinology of parturition, vol. 27. (Basel:Karger Publishers) (2001). p. 216–28.
15. Vacher CM, Lacaille H, O’Reilly JJ, Salzbank J, Bakalar D, Sebaoui S, et al. Placental endocrine function shapes cerebellar development and social behavior. Nat Neurosci (2021) 24(10):1392–401. doi: 10.1038/s41593-021-00896-4
16. Follesa P, Concas A, Porcu P, Sanna E, Serra M, Mostallino MC, et al. Role of allopregnanolone in regulation of GABAA receptor plasticity during long-term exposure to and withdrawal from progesterone. Brain Res Rev (2001) 37(1-3):81–90. doi: 10.1016/S0165-0173(01)00125-4
17. Belelli D, Lambert JJ. Neurosteroids: endogenous regulators of the GABAA receptor. Nat Rev Neurosci (2005) 6(7):565–75. doi: 10.1038/nrn1703
18. Hosie AM, Wilkins ME, da Silva HM, Smart TG. Endogenous neurosteroids regulate GABA a receptors through two discrete transmembrane sites. Nature (2006) 444(7118):486. doi: 10.1038/nature05324
19. Represa A, Ben-Ari Y. Trophic actions of GABA on neuronal development. Trends Neurosci (2005) 28(6):278–83. doi: 10.1016/j.tins.2005.03.010
20. Brinton RD. Neurosteroids as regenerative agents in the brain: Therapeutic implications. Nat Rev Endocrinol (2013) 9(4):241. doi: 10.1038/nrendo.2013.31
21. Wang JM, Brinton RD. Allopregnanolone-induced rise in intracellular calcium in embryonic hippocampal neurons parallels their proliferative potential. BMC Neurosci (2008) 9(2):S11. doi: 10.1186/1471-2202-9-S2-S11
22. Wang JM, Johnston PB, Ball BG, Brinton RD. The neurosteroid allopregnanolone promotes proliferation of rodent and human neural progenitor cells and regulates cell-cycle gene and protein expression. J Neurosci (2005) 25(19):4706–18. doi: 10.1523/JNEUROSCI.4520-04.2005
23. Gago N, el-Etr M, Sananès N, Cadepond F, Samuel D, Avellana-Adalid V, et al. 3alpha, 5alpha-tetrahydroprogesterone (allopregnanolone) and GABA: Autocrine/paracrine interactions in the control of neonatal PSA-NCAM+ progenitor proliferation. J Neurosci Res (2004) 78:770–83. doi: 10.1002/jnr.20348
24. Irwin RW, Singh C, Liu L, Wang J, Yao J, Chen S, et al. Allopregnanolone promotes neurogenesis, restores cognitive function and reduces alzheimer’s pathology in adult triple transgenic alzheimer’s mice: Preclinical development and formulation. Alzheimer’s Dementia: J Alzheimer’s Assoc (2010) 6(4):S560. doi: 10.1016/j.jalz.2010.05.1911
25. Tronnes AA, Koschnitzky J, Daza R, Hitti J, Ramirez JM, Hevner R. Effects of lipopolysaccharide and progesterone exposures on embryonic cerebral cortex development in mice. Reprod Sci (2016) 23(6):771–8. doi: 10.1177/1933719115618273
26. Kelleher MA, Palliser HK, Walker DW, Hirst JJ. Sex-dependent effect of a low neurosteroid environment and intrauterine growth restriction on foetal guinea pig brain development. J Endocrinol (2011) 208(3):301–9. doi: 10.1677/JOE-10-0248
27. Nguyen PN, Billiards SS, Walker DW, Hirst JJ. Changes in 5α-pregnane steroids and neurosteroidogenic enxyme expression in fetal sheep with umbilicoplacental embolization. Pediatr Res (2003) 54:840–7. doi: 10.1203/01.PDR.0000088066.47755.36
29. Noctor SC, Martinez-Cerdeno V, Kriegstein AR. Distinct behaviors of neural stem and progenitor cells underlie cortical neurogenesis. J Comp Neurol (2008) 508(1):28–44. doi: 10.1002/cne.21669
30. Toma K, Hanashima C. Switching modes in corticogenesis: mechanisms of neuronal subtype transitions and integration in the cerebral cortex. Front Neurosci (2015) 9:274. doi: 10.3389/fnins.2015.00274
31. Wang DD, Kriegstein AR. Defining the role of GABA in cortical development. J Physiol (2009) 587(9):1873–9. doi: 10.1113/jphysiol.2008.167635
32. Bicikova M, Klak J, Hill M, Zizka Z, Hampl R, Calda P. Two neuroactive steroids in midpregnancy as measured in maternal and fetal sera and in amniotic fluid. Steroids (2002) 67(5):399–402. doi: 10.1016/S0039-128X(01)00196-9
33. Hirst JJ, Palliser HK, Yates DM, Yawno T, Walker DW. Neurosteroids in the fetus and neonate: Potential protective role in compromised pregnancies. Neurochem Int (2008) 52(4-5):602–10. doi: 10.1016/j.neuint.2007.07.018
34. Molnar Z, Clowry GJ, Sestan N, Alzu’bi A, Bakken T, Hevner RF, et al. New insights into the development of the human cerebral cortex. J Anat (2019) 235(3):432–51. doi: 10.1111/joa.13055
35. DeFelipe J, Alonso-Nanclares L, Arellano JI. Microstructure of the neocortex: Comparative aspects. J Neurocytol (2002) 31(3-5):299–316. doi: 10.1023/A:1024130211265
36. Richman DP, Stewart RM, Hutchinson JW, Caviness VS Jr. Mechanical model of brain convolutional development. Science (1975) 189(4196):18–21. doi: 10.1126/science.1135626
37. Crossley KJ, Walker DW, Beart PM, Hirst JJ. Characterisation of GABA(A) receptors in fetal, neonatal and adult ovine brain: Region and age related changes and the effects of allopregnanolone. Neuropharmacology (2000) 39(9):1514–22. doi: 10.1016/S0028-3908(99)00222-1
38. Puia G, Santi M, Vicini S, Britchett DB, Purdy RH, Paul SM, et al. Neurosteroids act on recombinant human GABAA receptors. Neuron (1990) 4(759-65):759–65. doi: 10.1016/0896-6273(90)90202-Q
39. Chang Y, Huang YL, Whiteaker P. Mechanisms of allosteric modulation og the cys-loop receptors. Pharmaceuticals (2010) 3(8):2592–09. doi: 10.3390/ph3082592
40. Zheleznova NN, Sedelnikova A, Weiss DS. Function and modulation of δ-containing GABAA receptors. Psychoneuroendocrinology (2009) 34S1:S67–73. doi: 10.1016/j.psyneuen.2009.08.010
41. Hosie AM, Clarke L, da Silva H, Smart TG. Conserved site for neurosteroid modulation of GABA a receptors. Neuropharmacology (2009) 56(1):149–54. doi: 10.1016/j.neuropharm.2008.07.050
42. Finn DA, Beadles-Bohling AS, Beckley EH, Ford MM, Gililland KR, Gorin-Meyer RE, et al. A new look at the 5α-reductase inhibitor finasteride. CNS Drug Rev (2006) 12(1):53–76. doi: 10.1111/j.1527-3458.2006.00053.x
43. Reddy DS, Jian K. The testosterone-derived neurosteroid androstanediol is a positive allosteric modulator of GABAA receptors. J Pharmacol Exp Ther (2010) 334(3):1031–41. doi: 10.1124/jpet.110.169854
44. Hirshburg JM, Kelsey PA, Therrien CA, Gvino AC, Reichenberg JS. Adverse effects and safety of 5-alpha reductase inhibitors (finasteride, dutasteride)): A systematic review. J Clin Aesthetic Dermatol (2016) 9(7):56–62.
45. Wenzel PL, Leone G. Expression of cre recombinase in early diploid trophoblast cells of the mouse placenta. Genesis (2007) 45(3):129–34. doi: 10.1002/dvg.20276
46. Lacaille H, Vacher CM, Penn AA. Preterm birth alters the maturation of the GABAergic system in the human prefrontal cortex. Front Mol Neurosci (2021) 14:827370. doi: 10.3389/fnmol.2021.827370
47. Buck SB, Bradford J, Gee KR, Agnew BJ, Clarke ST, Salic A. Detection of s-phase cell cycle progression using 5-ethynyl-2’-deoxyuridine incorporation with click chemistry, an alternative to using 5-bromo-2’-deoxyuridine antibodies. Biotechniques (2008) 44(7):927–9. doi: 10.2144/000112812
48. Gerdes J, Lemke H, Baisch H, Wacker H-H, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody ki-67. J Immunol (1984) 133(4):1710–5.
49. Martynoga B, Morrison H, Price DJ, Mason JO. Foxg1 is required for specification of ventral telencephalon and region-specific regulation of dorsal telencephalic precursor proliferation and apoptosis. Dev Biol (2005) 283(1):113–27. doi: 10.1016/j.ydbio.2005.04.005
50. Shibui S, Hoshino T, Vanderlaan M, Gray JW. Double labeling with iodo- and bromodeoxyuridine for cell kinetics studies. J Histochem Cytochem (1989) 37(7):1007–11. doi: 10.1177/37.7.2659659
51. Cahill LS, Laliberte CL, Ellegood J, Spring S, Gleave JA, Eede MC, et al. Preparation of fixed mouse brains for MRI. Neuroimage (2012) 60(2):933–9. doi: 10.1016/j.neuroimage.2012.01.100
52. de Guzman AE, Wong MD, Gleave JA, Nieman BJ. Variations in post-perfusion immersion fixation and storage alter MRI measurements of mouse brain morphometry. Neuroimage (2016) 142:687–95. doi: 10.1016/j.neuroimage.2016.06.028
53. Lerch JP, Sled JG, Henkelman RM. MRI Phenotyping of genetically altered mice. Methods Mol Biol (2011) 711:349–61. doi: 10.1007/978-1-61737-992-5_17
54. Nieman BJ, Flenniken AM, Adamson SL, Henkelman RM, Sled JG. Anatomical phenotyping in the brain and skull of a mutant mouse by magnetic resonance imaging and computed tomography. Physiol Genomics (2006) 24(2):154–62. doi: 10.1152/physiolgenomics.00217.2005
55. Jones DK, Horsfield MA, Simmons A. Optimal strategies for measuring diffusion in anisotropic systems by magnetic resonance imaging. Magn Reson Med (1999) 42(3):515–25. doi: 10.1002/(SICI)1522-2594(199909)42:3<515::AID-MRM14>3.0.CO;2-Q
56. Collins DL, Neelin P, Peters TM, Evans AC. Automatic 3D intersubject registration of MR volumetric data in standardized talairach space. J Comput Assist Tomogr (1994) 18(2):192–205. doi: 10.1097/00004728-199403000-00005
57. Avants BB, Tustison NJ, Song G, Cook PA, Klein A, Gee JC. A reproducible evaluation of ANTs similarity metric performance in brain image registration. Neuroimage (2011) 54(3):2033–44. doi: 10.1016/j.neuroimage.2010.09.025
58. Douglas RJ. The development of hippocampal function: Implications for theory and for therapy. Hippocampus: Springer (1975) p:327–61. doi: 10.1007/978-1-4684-2979-4_11
59. Hughes RN. The value of spontaneous alternation behavior (SAB) as a test of retention in pharmacological investigations of memory. Neurosci Biobehav Rev (2004) 28(5):497–505. doi: 10.1016/j.neubiorev.2004.06.006
60. Ennaceur A. One-trial object recognition in rats and mice: methodological and theoretical issues. Behav Brain Res (2010) 215(2):244–54. doi: 10.1016/j.bbr.2009.12.036
61. Keller EA, Zamparini A, Borodinsky LN, Gravielle MC, Fiszman ML. Role of allopregnanolone on cerebellar granule cells neurogenesis. Brain Res Dev Brain Res (2004) 153(1):13–7. doi: 10.1016/j.devbrainres.2004.07.009
62. Singh C, Liu L, Wang JM, Irwin RW, Yao J, Chen S, et al. Allopregnanolone restores hippocampal-dependent learning and memory and neural progenitor survival in aging 3xTgAD and nonTg mice. Neurobiol Aging (2012) 33(8):1493–506. doi: 10.1016/j.neurobiolaging.2011.06.008
63. Gillardon F, Wickert H, Zimmermann M. Up-regulation of bax and down-regulation of bcl-2 is associated with kainate-induced apoptosis in mouse brain. Neurosci Lett (1995) 192(2):85–8. doi: 10.1016/0304-3940(95)11619-8
64. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, bax, that accelerates programmed cell death. Cell (1993) 74(4):609–19. doi: 10.1016/0092-8674(93)90509-O
65. Garcia MT, Chang YJ, Arai Y, Huttner WB. S-phase duration is the main target of cell cycle regulation in neural progenitors of developing ferret neocortex. J Comp Neurol (2016) 242(3):456–70. doi: 10.1002/cne.23801
66. Britanova O, de Juan Romero C, Cheung A, Kwan KY, Schwark M, Gyorgy A, et al. Satb2 is a postmitotic determinant for upper-layer neuron specification in the neocortex. Neuron (2008) 57(3):378–92. doi: 10.1016/j.neuron.2007.12.028
67. Chen B, Wang SS, Hattox AM, Rayburn H, Nelson SB, McConnell SK. The Fezf2–Ctip2 genetic pathway regulates the fate choice of subcortical projection neurons in the developing cerebral cortex. Proc Natl Acad Sci (2008) 105(32):11382–7. doi: 10.1073/pnas.0804918105
68. Alcamo EA, Chirivella L, Dautzenberg M, Dobreva G, Fariñas I, Grosschedl R, et al. Satb2 regulates callosal projection neuron identity in the developing cerebral cortex. Neuron (2008) 57(3):364–77. doi: 10.1016/j.neuron.2007.12.012
69. Reiss AL, Kesler SR, Vohr B, Duncan CC, Katz KH, Pajot S, et al. Sex differences in cerebral volumes of 8-year-olds born preterm. J Pediatr (2004) 145(2):242–9. doi: 10.1016/j.jpeds.2004.04.031
70. van Tilborg E, de Theije CGM, van Hal M, Wagenaar N, de Vries LS, Benders MJ, et al. Origin and dynamics of oligodendrocytes in the developing brain: Implications for perinatal white matter injury. Glia (2018) 66(2):221–38. doi: 10.1002/glia.23256
71. Faroni A, Magnaghi V. The neurosteroid allopregnanolone modulates specific functions in central and peripheral glial cells. Front Endocrinol (Lausanne) (2011) 2:103. doi: 10.3389/fendo.2011.00103
72. Zamora-Sanchez CJ, Del Moral-Morales A, Hernandez-Vega AM, Hansberg-Pastor V, Salido-Guadarrama I, Rodriguez-Dorantes M, et al. Allopregnanolone alters the gene expression profile of human glioblastoma cells. Int J Mol Sci (2018) 19(3):864. doi: 10.3390/ijms19030864
73. Chen S, Wang T, Yao J, Brinton RD. Allopregnanolone promotes neuronal and oligodendrocyte differentiation In vitro and In vivo: Therapeutic implication for alzheimer’s disease. Neurotherapeutics (2020) 17(4):1813–24. doi: 10.1007/s13311-020-00874-x
74. Evans J, Sun Y, McGregor A, Connor B. Allopregnanolone regulates neurogenesis and depressive/anxiety-like behaviour in a social isolation rodent model of chronic stress. Neuropharmacology (2012) 63(8):1315–26. doi: 10.1016/j.neuropharm.2012.08.012
75. Garcia-Garcia E, Pino-Barrio MJ, Lopez-Medina L, Martinez-Serrano A. Intermediate progenitors are increased by lengthening of the cell cycle through calcium signaling and p53 expression in human neural progenitors. Mol Biol Cell (2012) 23(7):1167–80. doi: 10.1091/mbc.e11-06-0524
76. Ben-Ari Y. Excitatory actions of gaba during development: The nature of the nurture. Nat Rev Neurosci (2002) 3(9):728–39. doi: 10.1038/nrn920
77. Cellot G, Cherubini E. GABAergic signaling as therapeutic target for autism spectrum disorders. Front. Pediatrics (2014).
78. Takahashi T, Nowakowski RS, Caviness VS Jr. The cell cycle of the pseudostratified ventricular epithelium of the embryonic murine cerebral wall. J Neurosci (1995) 15(9):6046–57. doi: 10.1523/JNEUROSCI.15-09-06046.1995
79. Mihalas AB, Elsen GE, Bedogni F, Daza RA, Ramos-Laguna KA, Arnold SJ, et al. Intermediate progenitor cohorts differentially generate cortical layers and require Tbr2 for timely acquisition of neuronal subtype identity. Cell Rep (2016) 16(1):92–105. doi: 10.1016/j.celrep.2016.05.072
80. Calegari F, Haubensak W, Haffner C, Huttner WB. Selective lengthening of the cell cycle in the neurogenic subpopulation of neural progenitor cells during mouse brain development. J Neurosci (2005) 25(28):6533–8. doi: 10.1523/JNEUROSCI.0778-05.2005
81. Lange C, Huttner WB, Calegari F. Cdk4/cyclinD1 overexpression in neural stem cells shortens G1, delays neurogenesis, and promotes the generation and expansion of basal progenitors. Cell Stem Cell (2009) 5(3):320–31. doi: 10.1016/j.stem.2009.05.026
82. Nagy Z, Lagercrantz H, Hutton C. Effects of preterm birth on cortical thickness measured in adolescence. Cereb Cortex (2010) 21(2):300–6. doi: 10.1093/cercor/bhq095
83. Nam KW, Castellanos N, Simmons A, Froudist-Walsh S, Allin MP, Walshe M, et al. Alterations in cortical thickness development in preterm-born individuals: Implications for high-order cognitive functions. Neuroimage (2015) 115(1):64–75. doi: 10.1016/j.neuroimage.2015.04.015
84. Nosarti C, Al-Asady MHS, Frangou S, Stewart AL, Rifkin L, Murray RM. Adolescents who were born very preterm have decreased brain volumes. Brain (2002) 125(7):1616–23. doi: 10.1093/brain/awf157
85. Skranes J, Løhaugen GC, Evensen KAI, Indredavik MS, Haraldseth O, Dale AM, et al. Entorhinal cortical thinning affects perceptual and cognitive functions in adolescents born preterm with very low birth weight (VLBW). Early Hum Dev (2012) 88(2):103–9. doi: 10.1016/j.earlhumdev.2011.07.017
86. Germain N, Banda E, Grabel L. Embryonic stem cell neurogenesis and neural specification. J Cell Biochem (2010) 111(3):535–42. doi: 10.1002/jcb.22747
87. Rodriguez-Tornos FM, Briz CG, Weiss LA, Sebastian-Serrano A, Ares S, Navarrete M, et al. Cux1 enables interhemispheric connections of layer II/III neurons by regulating Kv1-dependent firing. Neuron (2016) 89(3):494–506. doi: 10.1016/j.neuron.2015.12.020
88. Kubo K-I, Deguchi K, Nagai T, Ito Y, Yoshida K, Endo T, et al. Association of impaired neuronal migration with cognitive deficits in extremely preterm infants. JCI Insight (2017) 2(10):e88609. doi: 10.1172/jci.insight.88609
89. Adesnik H, Naka A. Cracking the function of layers in the sensory cortex. Neuron (2018) 100(5):1028–43. doi: 10.1016/j.neuron.2018.10.032
90. Aronoff R, Matyas F, Mateo C, Ciron C, Schneider B, Peterson CCH. Long-range connectivity of mouse primary somatosensory barrel cortex. Eur J Neurosci (2010) 31(12):2221–33. doi: 10.1111/j.1460-9568.2010.07264.x
91. Peterson CCH. The functional organization of the barrel cortex. Neuron (2007) 56(2):339–55. doi: 10.1016/j.neuron.2007.09.017
92. Quiquempoix, Fayad SK, Boutourlinsky K, Leresche N, RC L, Bessaig T. Layer 2/3 pyramidal neurons control the gain of cortical output. Cell Rep (2018) 24(1):2799–807. doi: 10.1016/j.celrep.2018.08.038
93. Walker SM, Mebourne A, O’Reilly H, Beckmann J, Eaton-Rosen Z, Ourselin S, et al. Somatosensory function and pain in extremely preterm young adults from the UK EPICure cohort: Sex-dependent differences and impact of neonatal surgery. Br J Anesthesia (2018) 121(3):623–35. doi: 10.1016/j.bja.2018.03.035
94. Adams JN, Feldman HM, Huffman LC, Loe IM. Sensory processing in preterm preschoolers and its association with executive function. Early Hum Dev (2015) 91(3):227–33. doi: 10.1016/j.earlhumdev.2015.01.013
95. Cabral TI, da Silva LGP, Martinez CMS, Tudella E. Analysis of sensory processing in preterm infants. Early Hum Dev (2016) 103:77–81. doi: 10.1016/j.earlhumdev.2016.06.010
96. Crozier SC, Goodson JZ, Mackay ML, Synnes AR, Grunau RE, Miller SP, et al. Sensory processing patterns in children born very preterm. Am J Occup Ther (2016) 70(1):7001220050p1–p7. doi: 10.5014/ajot.2016.018747
97. Gourley L, Wind C, Henninger EM, Chinitz S. Sensory processing difficulties, behavioral problems, and parental stress in a clinical population of young children. J Child Family Stud (2013) 22(7):912–21. doi: 10.1007/s10826-012-9650-9
98. Hynd GW, Semrud-Clikeman M, Lorys AR, Novey ES, Eliopulos D, Lyytinen H. Corpus callosum morphology in attention deficit-hyperactivity disorder: Morphometric analysis of MRI. J Learn Disabilities (1991) 24(3):141–6. doi: 10.1177/002221949102400302
99. Just MA, Cherkassky VL, Keller TA, Kana RK, Minshew NJ. Functional and anatomical cortical underconnectivity in autism: Evidence from an FMRI study of an executive function task and corpus callosum morphometry. Cereb Cortex (2006) 17(4):951–61. doi: 10.1093/cercor/bhl006
100. Cherkes-Julkowski M. Learning disability, attention-deficit disorder, and language impairment as outcomes of prematurity: A longitudinal descriptive study. J Learn Disabilities (1998) 31(3):294–306. doi: 10.1177/002221949803100309
101. Limperopoulos C. Autism spectrum disorders in survivors of extreme prematurity. Clinics Perinatol (2009) 36(4):791–805. doi: 10.1016/j.clp.2009.07.010
102. Lou H. Etiology and pathogenesis of attention-deficit hyperactivity disorder (ADHD): Significance of prematurity and perinatal hypoxic-haemodynamic encephalopathy. Acta Paediatrica (1996) 85(11):1266–71. doi: 10.1111/j.1651-2227.1996.tb13909.x
103. Nevalainen P, Pihko E, Metsaranta M, Andersson S, Autti T, Lauronen L. Does very premature birth affect the functioning of the somatosensory cortex? — A magnetoencephalography study. Int J Psychophysiol (2008) 68(2):85–93. doi: 10.1016/j.ijpsycho.2007.10.014
104. Stolp HB, Ball G, So PW, Tournier JD, Jones M, Thornton C, et al. Voxel-wise comparisons of cellular microstructure and diffusion-MRI in mouse hippocampus using 3D bridging of optically-clear histology with neuroimaging data (3D-BOND). Sci Rep (2018) 8(1):4011. doi: 10.1038/s41598-018-22295-9
105. McCarthy MM, Davis AM, Mong JA. Excitatory neurotransmission and sexual differentiation of the brain. Brain Res Bull (1997) 44(4):487–95. doi: 10.1016/S0361-9230(97)00230-X
106. Pandya M, Palpagma TH, Turner C, Waldvogel HJ, Faull RL, Kwakowsky A. Sex- and age-related changes in GABA signaling components in the human cortex. Biol Sex Differences (2019) 10(1):5. doi: 10.1186/s13293-018-0214-6
107. McCarthy MM, Auger AP, Perrot-Sinal TS. Getting excited about GABA and sex differences in the brain. Trends Neurosci (2002) 25(6):307–12. doi: 10.1016/S0166-2236(02)02182-3
Keywords: neuroplacentology, allopregnanolone (3α,5α-THP), somatosensory cortex (S1), placenta, postmortem human brain, preterm birth, GABAA receptor (GABAAR)
Citation: Bakalar D, O’Reilly JJ, Lacaille H, Salzbank J, Ellegood J, Lerch JP, Sasaki T, Imamura Y, Hashimoto-Torii K, Vacher C-M and Penn AA (2022) Lack of placental neurosteroid alters cortical development and female somatosensory function. Front. Endocrinol. 13:972033. doi: 10.3389/fendo.2022.972033
Received: 17 June 2022; Accepted: 28 September 2022;
Published: 13 October 2022.
Edited by:
Neil James MacLusky, University of Guelph, CanadaReviewed by:
Shogo Haraguchi, Showa University, JapanAida Bairam, Laval University, Canada
Jonathan James Hirst, The University of Newcastle, Australia
Mauricio Schuler Nin, Federal University of Rio Grande, Brazil
Copyright © 2022 Bakalar, O’Reilly, Lacaille, Salzbank, Ellegood, Lerch, Sasaki, Imamura, Hashimoto-Torii, Vacher and Penn. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Claire-Marie Vacher, cv2494@cumc.columbia.edu; Anna A. Penn, aap2216@cumc.columbia.edu
†Present address: Dana Bakalar, National Institute of Mental Health, NIH, Bethesda, MD, United States
Toru Sasaki, Nagaoka University of Technology, Nagaoka, Japan
‡These authors share last authorship